Nonsense suppression drug restores function in a mouse model of aniridia

Congenital aniridia is a progressive disease that is associated with improper development of eye structures as well as abnormalities in the brain and pancreas. A variety of nonsense mutations in the PAX6 gene are linked with aniridia; however, despite understanding the genetic basis of the disease, few treatment and prevention strategies are available.

In this issue of the Journal of Clinical Investigation, Cheryl Gregory-Evans and colleagues at the University of British Columbia evaluated a small molecule nonsense suppression strategy for relief of aniridia-associated defects in a mouse model of the disease. The authors developed a formulation of the nonsense suppression drug ataluren that could be given topically to postnatal aniridia mice. Administration of their ataluren-based formulation inhibited disease progression, reversed eye deformations, and restored eye function in aniridia mice.

In an accompanying commentary, José-Alain Sahel and Katia Marazova of the Institut de la Vision suggest that ataluren administration should be further explored as a therapeutic option for treatment of congenital eye defects associated with .

More information: Postnatal manipulation of Pax6 dosage reverses congenital tissue malformation defects, J Clin Invest. DOI: 10.1172/JCI70462
Toward postnatal reversal of ocular congenital malformations, J Clin Invest. 2014;124(1):81–84. DOI: 10.1172/JCI73560

Related Stories

Scientists use drug to repair rare birth defect

date Dec 20, 2013

University of British Columbia and Vancouver Coastal Health scientists have developed a potential cure for a rare eye disease, showing for the first time that a drug can repair a birth defect.

Rare eye disease leaves people without an iris

date Aug 02, 2013

(HealthDay)—You may never have heard of aniridia, a genetic disorder that robs people of their vision. But researchers studying the condition say it could give insight into some common health problems—from ...

New finding in rare eye disease

date Jul 14, 2008

(PhysOrg.com) -- Researchers have made a finding which could pave the way for new treatments for sufferers of a rare eye disease which can lead to blindness.

Recommended for you

Blood test may shed new light on Fragile X related disorders

date Mar 26, 2015

A blood test may shed new light on Fragile X syndrome related disorders in women, according to a new study published in the March 25, 2015, online issue of Neurology, the medical journal of the American Academy of Neurol ...

Recycling histones through transcription

date Mar 26, 2015

Cells reuse a part of the histones which are used to pack DNA, according to a current study by Karolinska Institutet. The study, which is published in the journal Genome Research, was conducted on yeast cells, but it is ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.